Literature DB >> 9351652

Tau phosphorylation in transgenic mice expressing glycogen synthase kinase-3beta transgenes.

J Brownlees1, N G Irving, J P Brion, B J Gibb, U Wagner, J Woodgett, C C Miller.   

Abstract

In order to investigate the effect on tau of manipulating glycogen synthase kinase (GSK)-3beta activity in the brain, we created transgenic mice harbouring wild-type GSK-3beta genes or a mutant GSK-3beta that is predicted to be more active. Transgene-derived mRNAs were detected in the brains of a number of the transgenic mouse lines and several of these transgenic lines displayed transgenic GSK-3beta activity. Western blot analyses of the two lines with the highest levels of transgenic GSK-3beta activity revealed that the phosphorylation status of tau was elevated at the AT8 epitope. These observations strongly suggest that GSK-3beta is an in vivo tau kinase in the brain. Only low levels of expression of GSK-3beta were obtained and it is possible that high levels of GSK-3beta activity are lethal.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9351652     DOI: 10.1097/00001756-199710200-00013

Source DB:  PubMed          Journal:  Neuroreport        ISSN: 0959-4965            Impact factor:   1.837


  21 in total

1.  Glycogen synthase kinase 3 phosphorylates kinesin light chains and negatively regulates kinesin-based motility.

Authors:  Gerardo Morfini; Györgyi Szebenyi; Ravindhra Elluru; Nancy Ratner; Scott T Brady
Journal:  EMBO J       Date:  2002-02-01       Impact factor: 11.598

2.  Expression of human apolipoprotein E4 in neurons causes hyperphosphorylation of protein tau in the brains of transgenic mice.

Authors:  I Tesseur; J Van Dorpe; K Spittaels; C Van den Haute; D Moechars; F Van Leuven
Journal:  Am J Pathol       Date:  2000-03       Impact factor: 4.307

3.  Hyperphosphorylated tau and neurofilament and cytoskeletal disruptions in mice overexpressing human p25, an activator of cdk5.

Authors:  M K Ahlijanian; N X Barrezueta; R D Williams; A Jakowski; K P Kowsz; S McCarthy; T Coskran; A Carlo; P A Seymour; J E Burkhardt; R B Nelson; J D McNeish
Journal:  Proc Natl Acad Sci U S A       Date:  2000-03-14       Impact factor: 11.205

4.  Spectroscopic studies of GSK3{beta} phosphorylation of the neuronal tau protein and its interaction with the N-terminal domain of apolipoprotein E.

Authors:  Arnaud Leroy; Isabelle Landrieu; Isabelle Huvent; Dominique Legrand; Bernadette Codeville; Jean-Michel Wieruszeski; Guy Lippens
Journal:  J Biol Chem       Date:  2010-08-02       Impact factor: 5.157

5.  β-Amyloid regulates leptin expression and tau phosphorylation through the mTORC1 signaling pathway.

Authors:  Gurdeep Marwarha; Bhanu Dasari; Jaya Prasanthi Rantham Prabhakara; Jared Schommer; Othman Ghribi
Journal:  J Neurochem       Date:  2010-08-25       Impact factor: 5.372

6.  Decreased nuclear beta-catenin, tau hyperphosphorylation and neurodegeneration in GSK-3beta conditional transgenic mice.

Authors:  J J Lucas; F Hernández; P Gómez-Ramos; M A Morán; R Hen; J Avila
Journal:  EMBO J       Date:  2001-01-15       Impact factor: 11.598

7.  Inhibition of GSK-3 ameliorates Abeta pathology in an adult-onset Drosophila model of Alzheimer's disease.

Authors:  Oyinkan Sofola; Fiona Kerr; Iain Rogers; Richard Killick; Hrvoje Augustin; Carina Gandy; Marcus J Allen; John Hardy; Simon Lovestone; Linda Partridge
Journal:  PLoS Genet       Date:  2010-09-02       Impact factor: 5.917

8.  Type 1 diabetes exaggerates features of Alzheimer's disease in APP transgenic mice.

Authors:  Corinne G Jolivalt; Rosemarie Hurford; Corinne A Lee; Wilmar Dumaop; Edward Rockenstein; Eliezer Masliah
Journal:  Exp Neurol       Date:  2009-11-18       Impact factor: 5.330

9.  Neurodegeneration and defective neurotransmission in a Caenorhabditis elegans model of tauopathy.

Authors:  Brian C Kraemer; Bin Zhang; James B Leverenz; James H Thomas; John Q Trojanowski; Gerard D Schellenberg
Journal:  Proc Natl Acad Sci U S A       Date:  2003-07-18       Impact factor: 11.205

10.  Clinical characterization of individuals with deletions of genes in holoprosencephaly pathways by aCGH refines the phenotypic spectrum of HPE.

Authors:  Jill A Rosenfeld; Blake C Ballif; Donna M Martin; Arthur S Aylsworth; Bassem A Bejjani; Beth S Torchia; Lisa G Shaffer
Journal:  Hum Genet       Date:  2010-04       Impact factor: 4.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.